<DOC>
	<DOCNO>NCT02951039</DOCNO>
	<brief_summary>In order understand risk benefit edoxaban use real-world clinical setting Non valvular Atrial Fibrillation ( NVAF ) indication , Daiichi-Sankyo propose non-interventional study gain insight safety ( bleed , liver adverse event , all-cause mortality drug relate adverse event ) efficacy edoxaban use non-preselected patient NVAF .</brief_summary>
	<brief_title>Edoxaban Treatment Routine Clinical Practice Patients With Atrial Fibrillation Korea Taiwan ( ETNA-AF-KOR-TWN )</brief_title>
	<detailed_description>Edoxaban approve Ministry Food Drug Safety ( MFDS ) Korea ( date : 25th , August 2015 ) reduction risk stroke systemic embolism patient NVAF , treatment deep vein thrombosis ( DVT ) pulmonary embolism . Edoxaban approve Taiwan Food Drug Administration ( TFDA ) Taiwan ( date : 24th , February , 2016 ) prevention stroke systemic embolism adult patient NVAF one risk factor , congestive heart failure , hypertension , age least 75 year , diabetes mellitus , prior stroke transient ischemic attack ( TIA ) , treatment deep vein thrombosis ( DVT ) pulmonary embolism ( PE ) , follow 5 10 day initial therapy parenteral anticoagulant . Real world evidence data routine clinical practice use edoxaban two year collect evaluate approximately 2,500 patient , treat specialized well non-specialized physician hospital center .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Edoxaban</mesh_term>
	<criteria>NVAFpatients treat edoxaban accord Summary Product Characteristics ( SmPC ) . Written inform consent participation study ( ICF ) . Not simultaneously participate interventional study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Non valvular Atrial Fibrillation</keyword>
	<keyword>Non-interventional Study</keyword>
	<keyword>Efficacy/Safety</keyword>
	<keyword>Real World Evidence</keyword>
</DOC>